166 related articles for article (PubMed ID: 25572818)
1. Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?
Sedef AM; Köse F; Sümbül AT; Doğan Ö; Beşen AA; Tatlı AM; Mertsoylu H; Sezer A; Muallaoğlu S; Özyılkan Ö; Abalı H
Med Oncol; 2015 Feb; 32(2):476. PubMed ID: 25572818
[TBL] [Abstract][Full Text] [Related]
2. Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group.
Murat Sedef A; Taner Sumbul FKA; Ayberk Besen A; Hacioglu B; Gunaldi M; Nayir E; Tanriverdi O; Arpaci E; Abali H; Ozyilkan O
J BUON; 2019; 24(2):650-655. PubMed ID: 31128019
[TBL] [Abstract][Full Text] [Related]
3. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
4. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer.
Kurt E; Cubukcu E; Karabulut B; Olmez OF; Kurt M; Avci N; Ozdemir F; Tunali D; Evrensel T; Manavoglu O
J BUON; 2013; 18(1):147-53. PubMed ID: 23613400
[TBL] [Abstract][Full Text] [Related]
7. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
10. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
13. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
Jiménez Fonseca P; Carmona-Bayonas A; Hernández R; Custodio A; Cano JM; Lacalle A; Echavarria I; Macias I; Mangas M; Visa L; Buxo E; Álvarez Manceñido F; Viudez A; Pericay C; Azkarate A; Ramchandani A; López C; Martinez de Castro E; Fernández Montes A; Longo F; Sánchez Bayona R; Limón ML; Diaz-Serrano A; Martin Carnicero A; Arias D; Cerdà P; Rivera F; Vieitez JM; Sánchez Cánovas M; Garrido M; Gallego J
Br J Cancer; 2017 Sep; 117(6):775-782. PubMed ID: 28765618
[TBL] [Abstract][Full Text] [Related]
14. Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer.
Kunisaki C; Takahashi M; Ono HA; Hasegawa S; Tsuchida K; Oshima T; Ota M; Fukushima T; Tokuhisa M; Izumisawa Y; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
Anticancer Res; 2013 Feb; 33(2):697-704. PubMed ID: 23393370
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
16. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.
Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK
Am J Surg Pathol; 2013 Jul; 37(7):1022-9. PubMed ID: 23715160
[TBL] [Abstract][Full Text] [Related]
17. Adding taxane to platin-5-fluorouracil combination does not improve survival rate in patients ≥ 65 years of age with advanced gastric cancer: A retrospective-multicenter study.
Gunaldi M; Kose F; Serkan Demirci N; Gunduz S; Ozdemir N; Kocoglu H; Okuturlar Y; Murat Sedef A; Erdem D; Sezgin Goksu S; Umut Erdem G; Yildirim M
J BUON; 2018; 23(2):416-421. PubMed ID: 29745086
[TBL] [Abstract][Full Text] [Related]
18. Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer.
Osumi H; Takahari D; Shinozaki E; Chin K; Ogura M; Wakatsuki T; Ichimura T; Nakayama I; Matsushima T; Yamaguchi K
Gastric Cancer; 2018 Mar; 21(2):267-275. PubMed ID: 28584889
[TBL] [Abstract][Full Text] [Related]
19. [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Wang Y; Xu JM; Liu JZ; Lin L; Ge FJ; Li SS; Liu LJ; Zhao CH
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):671-5. PubMed ID: 22340047
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
